Lupin gets FDA approval for Cefdinir

By Elaine Rigoli

Tampa, Fla., May 24 - Lupin Ltd. said the Food and Drug Administration has approved the company's abbreviated New Drug Application for Cefdinir capsules 300 mg administered orally to treat a wide variety of bacterial infections.

Cefdinir is being marketed by Abbott under the brand name Omnicef, which had sales of $634 million in 2005, according to a news release.

Based in Mumbai, India, Lupin develops generic intermediates, active pharmaceutical ingredients and finished dosages.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.